Financial Contrast: Danaher (NYSE:DHR) & Zicix (OTCMKTS:ZICXD)

Danaher (NYSE:DHR) and Zicix (OTCMKTS:ZICXD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Earnings and Valuation

This table compares Danaher and Zicix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.57 billion	5.12	$3.61 billion	$5.17	34.38
Zicix	N/A	N/A	N/A	($100.14)	-0.01

Danaher has higher revenue and earnings than Zicix. Zicix is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Danaher has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Zicix has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Insider & Institutional Ownership

79.1% of Danaher shares are owned by institutional investors. 10.8% of Danaher shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Danaher and Zicix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Danaher	14.89%	10.91%	6.94%
Zicix	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Danaher and Zicix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0	5	19	1	2.84
Zicix	0	0	0	0	0.00

Danaher presently has a consensus target price of $233.61, suggesting a potential upside of 31.43%. Given Danaher’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Danaher is more favorable than Zicix.

Summary

Danaher beats Zicix on 13 of the 13 factors compared between the two stocks.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.